In Vivo Roles of a Patient-Derived Induced Pluripotent Stem Cell Line (HD72-iPSC) in the YAC128 Model of Huntington’s Disease

Iksoo Jeon1, Chunggab Choi1, Nayeon Lee1, Wooseok Im2, Manho Kim2, Seung-Hun Oh3, In-Hyun Park4, Hyun Sook Kim3, Jihwan Song1

1CHA Stem Cell Institute, CHA University, 2Department of Neurology, Biomedical Research Institute, Seoul National University Hospital, Seoul, 3Department of Neurology, CHA Bundang Medical Center, CHA University, Seongnam, Korea 4Department of Genetics, Yale University School of Medicine, New Haven, USA

Induced pluripotent stem cells (iPSCs) generated from somatic cells of patients can provide immense opportunities to model human diseases, which may lead to develop novel therapeutics. Huntington’s disease (HD) is a devastating neurodegenerative genetic disease, with no available therapeutic options at the moment. We recently reported the characteristics of a HD patient-derived iPSC carrying 72 CAG repeats (HD72-iPSC). In this study, we investigated the in vivo roles of HD72-iPSC in the YAC128 transgenic mice, a commonly used HD mouse model carrying 128 CAG repeats. To do this, we transplanted HD72-iPSC-derived neural precursors into the striatum of YAC128 mice bilaterally and observed a significant behavioral improvement in the grafted mice. Interestingly, the transplanted HD72-iPSC-derived neural precursors formed GABAergic neurons efficiently, but no EM48-positive protein aggregates were detected at 12 weeks after transplantation. Taken together, these results indicate no HD pathology was developed from the grafted cells, or no transmission of HD pathology from the host to the graft occurred at 12 weeks post-transplantation.

Keywords: Huntington’s disease (HD), Induced pluripotent stem cells (iPSCs), YAC128 transgenic mice, GABAergic neurons, Aggregate formation

Introduction

Induced pluripotent stem cells (iPSCs) generated by reprogramming of fully differentiated somatic cells from patients into self-renewing pluripotent stem cells has completely transformed our ability to study disease in human cells (1, 2). Using iPSC technology, it is possible to create both genetically inherited and sporadic diseases in vitro (3). Moreover, since iPSCs can be derived directly from patients with a given disease, they carry all of the genetic components associated with the disease, which make certain cell types more susceptible to a disease state, thereby serving as the most useful genetic model of the disease (4).

Huntington’s disease (HD) is a devastating neurodegenerative genetic disease, caused by abnormal expansion of CAG repeats in the huntingtin (HTT) gene (5). Clinical features of HD include progressive motor dysfunction, cognitive decline, and psychiatric disturbance, probably caused by both neuronal dysfunction and neuronal cell death (6). Pathological hallmark of HD is the formation of aggregated huntingtin inclusion in the cytoplasm and nucleus, characterized by the expression of EM48 (7, 8). Despite numerous efforts, there are no avail-
able therapeutic options for HD at the moment (9).

We recently reported the characteristics of a HD patient-derived iPSC carrying 72 CAG repeats (HD72-iPSC) (10, 11). In this study, we investigated the in vivo roles of HD72-iPSC in the YAC128 transgenic mice, carrying the entire 170-kb genomic locus of human HTT gene plus 25 kb of the 5' flanking sequence and about 120 kb of 3' flanking sequence, which is commonly used as a preclinical model in HD (12). To do this, we transplanted HD72-iPSC-derived neural precursors into the striatum of YAC128 mice bilaterally and observed a significant behavioral improvement in the grafted mice. Interestingly, the transplanted HD72-iPSC-derived neural precursors formed GABAergic neurons efficiently, but no EM48-positive protein aggregates were detected at 12 weeks after transplantation. Taken together, these results indicate no HD pathology was developed from the grafted cells, or no transmission of HD pathology from the host to the graft occurred at 12 weeks post-transplantation, which will provide useful insights on the in vivo function and pathogenic effects of HD patient-derived iPSCs.

Materials and Methods

Culture and neuronal differentiation of HD72-iPSC

We cultured and maintained HD72-iPSC according to the method described previously (10). Neuronal differentiation was induced by co-culturing HD72-iPSC with PA6 stromal cells (obtained from RIKEN Cell Bank, Ibaraki, Japan) (13). Using the 5-stage protocol, we initially induced neural rosette-like structures, detached them mechanically and formed neurospheres in suspension culture. To make neural precursor cells, we dissociated neurospheres following treatment with Accutase® (Chemicon, Temecula, CA, USA) and plated onto poly-L-ornithine (PLO; 15 μg/ml, Sigma, Sigma, St. Louis, MO, USA)/fibronectin (FN; 1 μg/ml, Sigma)-coated 60 mm² tissue culture dishes. Neural precursor cells were maintained in GMEM supplemented with 1% N2 supplements and 20 ng/ml bFGF (Invitrogen, Carlsbad, CA, USA).

YAC128 transgenic mice and cell transplantation

We performed animal experiments in accordance with the CHA University IACUC (Institutional Animal Care and Use Committee; IACUC090012). YAC128 mice (FVB-Tg(YAC128)53Hay/J) were originally purchased from the Jackson Laboratory (Bar Harbor, ME, USA), and 12 month-old mice were used in transplantation experiments. We stereotaxically injected a total of 15 mice with 1 μl of HD72 iPSC-derived neural precursor cells (100,000 cells/μl) into the striatum of both hemispheres using the following coordinates: AP +0.5 mm, ML ±1.75 mm and DV −2.5 mm from the Bregma. In the sham group (n=15), 1 μl of suspension medium (GMEM) were injected into both hemispheres in parallel. Uninjected YAC128 wild-type littermates were included as a control group (n=14). Both cell-transplanted and medium-injected animals were received cyclosporine A intraperitoneally (5 mg/kg, Sigma) 24 h before transplantation and daily up to 12 weeks.

Behavioral test

Rotarod test was performed, in which mice were placed on the rod with an accelerating rotating speed from 4 to 40 rpm over a period of 3 minutes with a 15 minutes rest between trials (14). Mice were trained on three consecutive days for three trials per day before transplantation. Three trials were performed and the mean latencies to fall were used to analyze data.

Statistical analysis

We performed statistical analyses on the rotarod scores using the Statistical Analysis System (Enterprise 4.1; SAS Korea) on a CHA University mainframe computer. Performance measures were analyzed using the PROC MIXED program, a linear mixed models procedure. A p value of <0.05 was considered significant.

Immunohistochemistry

To investigate the pathological features of YAC128 mice, we sacrificed the 12 month-old YAC128 mice and their wild-type littermates, perfused and fixed their brains with 4% paraformaldehyde. 30 μm frozen coronal sections were prepared using a cryostat (Microm, Walldorf, Germany). A conventional DAB (3,3'-diaminobenzidine) immunohistochemistry using antibodies for DARPP-32 (1:100, Cell Signaling Technology, Danvers, MA, USA) and EM48 (1:50, Chemicon) was performed. To analyze the marker expression from the transplanted cells, we sacrificed the transplanted mice at 12 week-post transplantation and performed fluorescence immunohistochemical analyses using the following primary antibodies: human-specific nuclei (hNu) (1:200, Chemicon), human-specific mitochondria (hMito) (1:200, Chemicon), human-specific Nestin (hNestin) (1:200, Chemicon), MAP2 (1:200, Chemicon), GAD6 (1:200, Developmental Studies Hybridoma Bank, Iowa City, IA, USA), Gamma-aminobutyric acid (GABA) (1:5000, Sigma), DARPP-32 (1:100, Cell Signaling), SVP38 (1:200, Sigma), EM48 (1:50, Chemicon). Secondary antibodies used were...
goat anti-mouse IgG-conjugated Alexa-555 (1:200, Molecular Probes), goat anti-rabbit IgG-conjugated Alexa-488 (1:200, Molecular Probes, Eugene, OR, USA) and goat anti-mouse IgM-conjugated Alexa-555 (1:200, Molecular Probes). We counter-stained the cells using DAPI, and photographed the staining patterns using a confocal laser-scanning microscope imaging system (LSM510, Carl Zeiss, Inc., Thornwood, NY, USA).

Results

Pathological features of YAC128 transgenic mice
We first examined the pathological characteristics of 12 month-old YAC128 transgenic mice, by which full-spectrum of neuronal loss and behavioral deficits are known to become evident (12). As expected, we observed the expression of DARPP-32, a marker for medium spiny neurons (MSNs) is significantly reduced, whereas the expression of EM48, a marker for aggregated mutant huntingtin protein (mHtt) is significantly increased in the transgenic mice (Fig. 1B and D, respectively), compared with their wild-type littermates (Fig. 1A and C, respectively).

Behavioral improvement following transplantation of HD72-iPSC-NPC cells into YAC128 mice
To address the in vivo roles of GABAergic neurons derived from HD72-iPSCs (10), we transplanted 100,000 HD72-iPSC-derived neural precursors, in a volume of 1 μl, into the striatum of both hemispheres of each YAC128 mice (n=15). In sham control mice (n=15) we only injected suspension medium (GMEM) into both hemispheres in parallel. Uninjected YAC128 wild-type littermates were included as a control group (n=14). To evaluate functional effects of the grafts, we employed rotarod test, because it has been shown that rotarod performance is greatly reduced in the YAC128 mice. They exhibit rotarod deficit initially at 4 months of age but become more prominent at 6 months of age (12). Poor performance on the rotarod represents motor learning deficits, indicating some aspects of cognitive functions are also affected in YAC128 mice. To our surprise, we observed a significant improvement of rotarod activity in the transplanted group at as early as three weeks after transplantation, compared with the sham controls (Fig. 2). Therefore, these results strongly suggest that HD72-iPSC-derived neural precursors played some beneficial roles after transplantation, although they carry genetic mutations.

Neuronal differentiation and pathology development from the transplanted HD72-iPSC-NPC
After completion of behavior test at 12 weeks, we sacrificed the mice and analyzed their brains histologically. To identify the transplanted human cells, we used antibodies against human-specific nuclear antigen (hNu) and human mitochondria (hMito). Using confocal microscopy and double immunostaining, we found that some of the transplanted HD-iPSC-derived cells were still Nestin-positive neural precursors (Fig. 3A). Importantly, a large number of the surviving human neurons were MAP2-positive (Fig. 3B), and some neurons exhibited GABAergic and MSN features, i.e., they were immunoreactive for GAD6 (Fig. 3C), GABA (Fig. 3D) and DARPP-32 (Fig. 3E). We also found that transplanted human cells expressed the syn-
Immunohistochemical analyses showing neuronal differentiation and pathology development from the transplanted HD72-iPSC-NPC. (A∼F) Formation of markers specific for Nestin (A), MAP2 (B), GAD6 (C), GABA (D), DARPP-32 (E), and SVP38 (F). Arrowheads indicate the co-localized cells. (G, H) Areas showing transplanted human cells do not co-localize with EM48 (G), or the host tissues expressing EM48 but devoid of transplanted human cells (H). (I) Co-localization of EM48 in the DARPP-32-positive cells. Asterisks indicate the co-localized cells. Scale bar: 50 μm.

Discussion

In this study, we investigated the in vivo roles of HD72-iPSC in the YAC128 transgenic mice, a commonly used preclinical mouse model of HD, carrying the entire 170-kb genomic locus of human HTT gene (12). To do this, we transplanted HD72-iPSC-derived neural precursors into the striatum of YAC128 mice bilaterally and observed a significant improvement in the rotarod performance. Interestingly, although they carry genetic mutations, the transplanted HD72-iPSC-derived neural precursors formed GABAergic and MSN-type neurons efficiently, and led to no obvious neuropathological development, judged by the absence of but EM48-positive protein aggregates at 12 weeks after transplantation. This ob-
servation was very similar to our recent report (10), in which the same type of cells were transplanted into the quinolinic acid-lesioned rodent model of HD. However, in the same report, we also showed that HD pathology can develop after ∼9 months in vivo (10), suggesting that cellular age may be a key factor in identifying aggregates in human HD-iPSCs (4). Therefore, it will be likely that the transplanted HD72-iPSC-derived neural precursors will give rise to EM48-positive aggregates at later stages. Another important aspect of results is that no EM48-positive aggregates were detected in the transplanted cells at 12 weeks post-transplantation, while the host tissue in the YAC128 mice normally expresses EM48. Moreover, DARPP-32-positive medium spiny neurons were already affected by EM48-positive aggregates. These results strongly indicate that no HD pathology was developed either from the transplanted cells, or no transmission of HD pathology from the host to the graft took place at 12 weeks post-transplantation. It will be interesting to investigate whether “host-to-graft” or “graft-to-host” transmission of HD pathology can occur at later stages. At the same time, it will be important to address whether and how normal iPSC-derived GABAergic neurons can contribute to the functional recovery and neuronal regeneration. In order these HD-iPSCs to be used for the cell therapy, it will essential to target the HTT mutation and correct it to a normal gene in the HD-iPSCS before transplantation (15). There are a wide range of HD-iPSC lines available through HD iPSC consortium (16), so it will be useful to uncover their pathogenic mechanisms in the future. Taken together, results from this study can provide useful insights on the in vivo function and pathogenic effects of human HD-iPSCs, as well as on the development of HD therapeutics in the future.

Acknowledgments
This study was supported by a grant of the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2012R1A1A2006827), Republic of Korea to J.S.

Potential conflict of interest
The authors have no conflicting financial interest.

References

1. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676
2. Okita K, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci 2011;366:2198-2207
3. Park IH, Arora N, Huo H, Maherali N, Ahfeldt T, Shimamura A, Lensch MW, Cowan C, Hochdedinger K, Daley GQ. Disease-specific induced pluripotent stem cells. Cell 2008;134:877-886
4. Kaye JA, Finkbeiner S. Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci 2013;56:50-64
5. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993;79:971-983
6. Walker FO. Huntington's disease. Lancet 2007;369:218-228
7. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997;277:1990-1993
8. Arrasate M, Finkbeiner S. Protein aggregates in Huntington's disease. Exp Neurol 2012;238:1-11
9. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011;10:83-98
10. Jeon I, Lee N, Li JY, Park IH, Park KS, Moon J, Shim SH, Choi C, Chang DJ, Kwon J, Oh SH, Shin DA, Kim HS, Do JT, Lee DR, Kim M, Kang KS, Daley GQ, Brundin P, Song J. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells 2012;30:2054-2062
11. Chae JJ, Kim DW, Lee N, Jeon YJ, Jeon I, Kwon J, Kim J, Soh Y, Lee DS, Soo KS, Choi NJ, Park BC, Kang SH, Ryu J, Oh SH, Shin DA, Lee DR, Do JT, Park IH, Daley GQ, Song J. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J 2012;446:359-371
12. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003;12:1555-1567
13. Kawasaki H, Mizuseki K, Nishikawa S, Kaneko S, Kuwana Y, Nakashishi S, Nishikawa SI, Sasai Y. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 2000;28:31-40
14. Im W, Ban J, Lim J, Lee M, Lee ST, Chu K, Kim M. Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease. PLoS One 2013;8:e59438
15. An MC, Zhang N, Scott G, Montoro D, Wittkop T, Mooney S, Melov S, Ellerby LM. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11:253-263
16. HD iPSC Consortium. Induced pluripotent stem cells from patients with Huntington's disease show CAG-repeat-expansion-associated phenotypes. Cell Stem Cell 2012;11:264-278